Community of Practice for Neuromuscular Allied Healthcare Members: MDC and NMD4C Begin Consultations
The Neuromuscular Disease Network for Canada in partnership with Muscular Dystrophy Canada, is investigating ways to better support allied healthcare professionals that work with clients/patients affected by neuromuscular disorders and their families.
We wish to introduce and implement a Community of Practice for allied healthcare professionals this year, but first we would like to complete a needs assessment and seek your valued input. Please take this brief survey before April 15th:
English: https://www.surveymonkey.com/r/NMAlliedHealthConsultation
French: https://www.surveymonkey.com/r/DMCCommunautedePratique
We will also be hosting virtual engagement sessions on April 6th and 7th to provide allied healthcare professionals with an opportunity to share their professional experiences, questions, concerns, and comments. If you would like to learn more about these consultations, please email Homira Osman at
We also ask that you circulate the above survey with your colleagues with clients/patients affected by neuromuscular disorders.
Read next...
Hope on the Horizon: Trials, Treatments and Therapies for DMD, DM1 & MG
Nov 25-28, 2025 | Join us at Hope on the Horizon to learn more about the treatment and clinical trial landscape for Duchenne Muscular Dystrophy, Myotonic Dystrophy Type 1 and Myasthenia Gravis from key experts in the field!
2026 Awards Now Open for Nominations!
We’re proud to recognize outstanding achievements across the neuromuscular research community with our Three awards: Publication of the Year, Early Career Biomedical/Clinical Researchers of the Year.
A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada
Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.